期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 8, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s13045-015-0194-5
关键词
Breast cancer; CDK4/CDK6 inhibitor; Palbociclib
资金
- Research Foundation at UCLA
Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy. In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in those who had progressed during prior endocrine therapy. This research highlight summarized the current development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据